284 related articles for article (PubMed ID: 36077002)
1. Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.
Ramdani Y; Lamamy J; Watier H; Gouilleux-Gruart V
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077002
[TBL] [Abstract][Full Text] [Related]
2. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
3. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
4. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.
Borrok MJ; Wu Y; Beyaz N; Yu XQ; Oganesyan V; Dall'Acqua WF; Tsui P
J Biol Chem; 2015 Feb; 290(7):4282-90. PubMed ID: 25538249
[TBL] [Abstract][Full Text] [Related]
5. Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.
Foss S; Grevys A; Sand KMK; Bern M; Blundell P; Michaelsen TE; Pleass RJ; Sandlie I; Andersen JT
J Control Release; 2016 Feb; 223():42-52. PubMed ID: 26718855
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
7. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
8. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
9. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.
Deng R; Meng YG; Hoyte K; Lutman J; Lu Y; Iyer S; DeForge LE; Theil FP; Fielder PJ; Prabhu S
MAbs; 2012; 4(1):101-9. PubMed ID: 22327433
[TBL] [Abstract][Full Text] [Related]
11. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
12. Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn.
Reusch J; Andersen JT; Rant U; Schlothauer T
MAbs; 2024; 16(1):2361585. PubMed ID: 38849969
[TBL] [Abstract][Full Text] [Related]
13. A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life.
Jensen PF; Schoch A; Larraillet V; Hilger M; Schlothauer T; Emrich T; Rand KD
Mol Cell Proteomics; 2017 Mar; 16(3):451-456. PubMed ID: 28062799
[TBL] [Abstract][Full Text] [Related]
14. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
15. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
16. Characterization and screening of IgG binding to the neonatal Fc receptor.
Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
[TBL] [Abstract][Full Text] [Related]
17. In Translation: FcRn across the Therapeutic Spectrum.
Qi T; Cao Y
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802650
[TBL] [Abstract][Full Text] [Related]
18. Methods for Functional Characterization of FcRn Interactions with Therapeutic Antibodies and Fc-Fusion Proteins.
Chung S; Lin YL; Nguyen V; Liu C
Methods Mol Biol; 2022; 2313():295-303. PubMed ID: 34478146
[TBL] [Abstract][Full Text] [Related]
19. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
Dall'Acqua WF; Kiener PA; Wu H
J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
[TBL] [Abstract][Full Text] [Related]
20. V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor.
Rossini S; Noé R; Daventure V; Lecerf M; Justesen S; Dimitrov JD
J Immunol; 2020 Nov; 205(10):2850-2860. PubMed ID: 33077645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]